Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion

Basit Öğe Kaydı
dc.contributor.authorKaraarslan, Numan
dc.contributor.authorDoğan, Mustafa
dc.contributor.authorBilir, Bülent
dc.contributor.authorYılmaz, İbrahim
dc.contributor.authorÖzbek, Hanefi
dc.date.accessioned2023-03-22T19:48:15Z
dc.date.available2023-03-22T19:48:15Z
dc.date.issued2022
dc.departmentBelirleneceken_US
dc.description.abstractAbstract Aim: Macrophage activation syndrome (MAS) develops due to increased expression of systemic pro-inflammatory cytokines in patients with the 2019 novel coronavirus disease (COVID-19). Immune modulators have been used in anti-cytokine therapy, with the hypothesis that they can ensure cytokine inhibition and treat cytokine storm. The present study aimed to evaluate inflammatory and prognostic biomarkers in severe COVID-19 cases treated with tocilizumab (TCZ) alone or with the combination of tocilizumab and convalescent plasma transfusion (CPT). Materials and Methods: In this retrospective study, data archives of patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and who were treated with TCZ alone or the combination of CPT and TCZ were evaluated in line with the literature. The obtained data were statistically evaluated and the alpha significance value was taken as <0.05. Results: Post-treatment C-reactive protein (CRP) (76.19% in TCZ-administered group; 89.32% in TCZ+CPT-administered group) (P<0.05), troponin I (TNI) (25.64% in TCZadministered group; 90.39% in TCZ+CPT-administered group) (P<0.05), and ferritin (FER) (63.63% in the TCZ-administered group; 9.09% in the TCZ+CPT-administered) (P<0.05) levels were decreased compared to pre-treatment stage. The mean length of hospital stay was longer in the patients treated with TCZ alone (21.55±8.89 days) than in the patients treated with the combination of TCZ and CPT (27.09±13.66 days) (P<0.05). Conclusion: There was no significant difference between the groups in terms of demographic characteristics. The combination of TCZ and CPT treatment did not decrease the mortality. A significant decrease in CRP and TNI levels was observed in the patients treated with TCZ alone and with the combination of TCZ and CPT. A decrease in FER levels showed the effectiveness of the treatments.en_US
dc.identifier.doi10.5455/annalsmedres.2022.02.048
dc.identifier.endpage776en_US
dc.identifier.issn2636-7688
dc.identifier.issue7en_US
dc.identifier.startpage770en_US
dc.identifier.trdizinid1119468en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1034
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2022.02.048
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1119468
dc.identifier.volume29en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.journalAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleEvaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion.pdf
Boyut:
2.89 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin / Full text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu